Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria
4.11.2024 22:12:00 EET | Business Wire | Press release
Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/
Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Prime Minister of Bulgaria; Elias Gedeon, Senior Vice President of Westinghouse Energy Systems; Kenneth Merten, U.S. Ambassador to Bulgaria; and Petyo Ivanov, Executive Director, Kozloduy NPP - New Build. (Photo: Business Wire)
The contract scope includes site planning for two Westinghouse AP1000® units, the most advanced Generation III+ nuclear reactor available today. In addition, the contract provides support for Kozloduy NPP - New Build EAD to begin licensing and permitting, while providing critical project planning and operations & maintenance development. The work outlined in the 12-month contract will begin immediately.
“Bulgaria has over 50 years of experience in the construction of nuclear facilities. And today's event will build on this experience and contribute to the independence, diversification and stability of nuclear energy in the country and throughout Europe. We are pleased to partner on the new build project with Westinghouse Electric Company and Hyundai Engineering & Construction, which are undisputed leaders in this field. I am convinced of the great success of the project, and the Bulgarian state will give its maximum for its successful implementation,” said Dimitar Glavchev, Bulgarian Prime Minister.
“The main priority of our cabinet is the development of nuclear energy. Our consistent efforts in this direction have led to today's event. We are thankful to Westinghouse Electric Company and Hyundai Engineering & Construction for responding to our request and forming a consortium. I believe that in less than 10 years we will have a working project that will be a guarantee for the Bulgarian population and country, that we will have clean energy at an affordable price,” said Vladimir Malinov, Bulgarian Minister of Energy.
“The United States fully supports Bulgaria’s efforts to ensure its energy security through the diversification of its energy sector. The construction of these two new reactors will both enhance Bulgaria’s energy security and position the country as a key energy hub for the region,” said Kenneth Merten, U.S. Ambassador to Bulgaria. “This project, using advanced American technology with unparalleled safety standards over years of safe operation, is poised to provide sustainable and secure energy for Bulgaria’s future.”
“We are pleased to extend our long-term relationship with Bulgaria, and to work closely in building two advanced AP1000 units that will bolster Bulgaria’s energy security,” said Dan Lipman, President of Westinghouse Energy Systems. “This project will not only deliver clean, safe and stable power to Bulgaria, it will also create high-quality jobs and real economic benefits for years to come and foster Bulgaria’s energy independence.”
Bulgaria’s first AP1000 nuclear reactor is anticipated to achieve commercial operation in 2035. Westinghouse has already signed Memoranda of Understanding with 22 Bulgarian suppliers to support the project. The two-unit Kozloduy project will also provide Bulgarian firms opportunities to support the more than 30 AP1000 units in the pipeline globally.
The AP1000 reactor is the only operating Generation III+ reactor with fully passive safety systems, modular construction design and the smallest footprint per MWe on the market. In China, there are four AP1000 reactors currently setting operational performance and availability records with eight additional reactors under construction and four more under contract. In addition, there are two operating AP1000 units at the Vogtle site in Georgia. The AP1000 technology has been selected for nuclear energy programs in Poland, Ukraine and Bulgaria, and is also under consideration at multiple other sites in Central and Eastern Europe, the United Kingdom, India and North America. There will be 18 units based on AP1000 technology in operation globally by the end of the decade.
Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear and other clean power technologies and services globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation makes Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104293861/en/
Contacts
media@westinghouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom